| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Kinesin-like protein KIF18A, Marrow stromal KIF18A, MS-KIF18A, KIF18A |
| Entrez GeneID | 81930 |
| WB Predicted band size | 102.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This KIF18A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 644-673 amino acids from the C-terminal region of human KIF18A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于KIF18A抗体的3篇代表性文献(内容为学术概括示例，非真实文献)：
1. **文献名称**：*KIF18A Depletion via Antibody Targeting Disrupts Mitotic Progression in Cancer Cells*
**作者**：Tanaka H, et al.
**摘要**：本研究利用特异性KIF18A抗体抑制其功能，发现其缺失导致癌细胞有丝分裂中期染色体排列异常，引发纺锤体组装检查点激活，最终诱导细胞凋亡，提示KIF18A抗体在癌症治疗中的潜力。
2. **文献名称**：*KIF18A as a Therapeutic Target in Chromosomal Instability-Driven Tumors*
**作者**：Zhang L, et al.
**摘要**：通过KIF18A抗体阻断实验，证实其在染色体不稳定性(CIN)肿瘤中的关键作用，抗体介导的KIF18A抑制可选择性杀伤CIN阳性癌细胞，为靶向治疗提供理论依据。
3. **文献名称**：*Development of a High-Affinity Anti-KIF18A Antibody for Functional Studies*
**作者**：Müller S, et al.
**摘要**：报道一种新型高亲和力KIF18A单克隆抗体的开发，该抗体能特异性识别KIF18A的ATP结合域，有效抑制其微管解聚活性，为研究有丝分裂调控机制提供了重要工具。
4. **文献名称**：*KIF18A Antibody-Based Screening Identifies Synthetic Lethality in BRCA1-Deficient Cells*
**作者**：Chen J, et al.
**摘要**：结合KIF18A抗体筛选发现，BRCA1缺陷细胞对KIF18A功能抑制高度敏感，揭示了其在合成致死疗法中的潜在应用价值，为乳腺癌治疗提供新策略。
(注：以上文献为示例性内容，实际研究需参考真实发表的学术论文。)
KIF18A (kinesin family member 18A) is a microtubule-associated motor protein belonging to the kinesin-8 family, primarily involved in regulating mitotic spindle dynamics and chromosome alignment during cell division. It plays a critical role in mitosis by controlling microtubule length and tension at kinetochores, ensuring accurate chromosome segregation. Dysregulation of KIF18A is linked to genomic instability, mitotic errors, and cancer progression, as its overexpression has been observed in various malignancies, including breast, liver, and ovarian cancers.
KIF18A antibodies are essential tools for studying its expression, localization, and function in cellular processes. These antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate KIF18A's role in mitotic regulation and its association with tumorigenesis. Recent studies explore KIF18A as a potential therapeutic target, with inhibitors under investigation for anticancer strategies. Researchers also utilize KIF18A antibodies to validate gene-editing outcomes (e.g., CRISPR/Cas9) and assess correlations between KIF18A levels and clinical outcomes in cancer patients. Specific antibody clones (e.g., monoclonal antibodies targeting distinct epitopes) are often characterized for species reactivity and application-specific validation to ensure experimental reproducibility.
×
